Power Law company profile

Aurinia Pharmaceuticals

Biotech & Life Sciences · Edmonton, Canada · Founded 1993 · IPO 1996 Unicorn

Late-stage biopharma developing therapies for serious diseases, including voclosporin for lupus nephritis, proteinuric diseases, and dry eye syndrome

Valuation

$1.68B

Market cap · May/2026

Revenue

$283M

Latest reported FY

EBITDA

$140M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where Aurinia Pharmaceuticals has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States93.5%

🇨🇦 Canada6.1%

🇬🇧 United Kingdom0.7%

3 countries shown

Web traffic by country

5.6K monthly visits
across markets

🇺🇸 United States75%

🇨🇦 Canada64.3%

🏳️ Korea5.4%

🏳️ Republic of0%

Top 4 markets shown

Patent intelligence

$136M patent portfolio · 66 active families

Estimated portfolio value

$136M

8.1% of market cap · 2.6× smaller than top peer Reata Pharmaceuticals ($354M)

66 active patent families

Where Aurinia Pharmaceuticals innovates Medicinal chemistryPharmaceutical drugPharmacologyDrugIron complex

Where Aurinia Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Aurinia Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Aurinia Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Aurinia Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aurinia Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles